公开(公告)号：EP1098961B1

公开(公告)日：2008-01-16

申请号：EP99927440.0

申请日：1999-06-11

申请人： MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK ,  Egorov, Andrej Y., Dr. ,  Muster, Thomas

发明人： EGOROV, Andrej Y., Dr. ,  MUSTER, Thomas ,  GARCIA-SASTRE, Adolfo ,  PALESE, Peter ,  BRANDT, Sabine

IPC分类号： C12N7/01 ,  C12N7/04 ,  C12N15/86 ,  A61K39/145 ,  A61K39/295

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/5256 ,  C07K14/005 ,  C12N15/86 ,  C12N2760/16121 ,  C12N2760/16122 ,  C12N2760/16132 ,  C12N2760/16134 ,  C12N2760/16161 ,  C12N2830/002 ,  Y02A50/412 ,  Y02A50/466

摘要： The present invention relates to genetically engineered attenuated viruses and methods for their production. In particular, the present invention relates to engineering live attenuated viruses which contain a modified NS gene segment. Recombinant DNA techniques can be utilized to engineer site specific mutations into one or more noncoding regions of the viral genome which result in the down-regulation of one or more viral genes. Alternatively, recombinant DNA techniques can be used to engineer a mutation, including but not limited to an insertion, deletion, or substitution of an amino acid residue(s) or an epitope(s) into a coding region of the viral genome so that altered or chimeric viral proteins are expressed by the engineered virus.

公开(公告)号：EP1086207B1

公开(公告)日：2007-01-17

申请号：EP99927443.4

申请日：1999-06-11

申请人： MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK

发明人： PALESE, Peter ,  GARCIA-SASTRE, Adolfo ,  O'NEIL, Robert

IPC分类号： C12N7/00 ,  A61K39/12

CPC分类号： A61K39/145 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/155 ,  A61K39/17 ,  A61K39/205 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/543 ,  A61K2039/552 ,  A61K2039/572 ,  A61K2039/585 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/16121 ,  C12N2760/16122 ,  C12N2760/16132 ,  C12N2760/16134 ,  C12N2760/16143 ,  C12N2760/16151 ,  C12N2760/16161 ,  C12N2760/16162 ,  C12N2760/16171 ,  C12N2760/16221 ,  C12N2760/16222 ,  C12N2760/16232 ,  C12N2760/16234 ,  C12N2760/16243 ,  C12N2760/16251 ,  C12N2760/16262 ,  C12N2760/16271 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18122 ,  C12N2760/18134 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/20222 ,  C12N2760/20234 ,  Y02A50/466

摘要： The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.

公开(公告)号：EP1034254B1

公开(公告)日：2008-04-30

申请号：EP98957581.6

申请日：1998-11-02

申请人： NEW YORK UNIVERSITY ,  MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK

发明人： LEVY, David ,  PALESE, Peter ,  GARCIA-SASTRE, Adolfo ,  DURBIN, Joan, Elizabeth

IPC分类号： C12N5/00 ,  C12N7/00

CPC分类号： C12N7/00 ,  C12N2510/04 ,  C12N2760/16151

摘要： The present invention is directed to immortalized STAT1-deficient mammalian cell lines. STAT1 is a signal transducer and activator of transcription that becomes phosphorylated when cells are treated with type I or type II interferons and leads to induction of specific gene expression, resulting in establishment of the antiviral state and the other known biological responses to interferons, including the inhibition of cell proliferation. Cells which lack this gene product are useful for producing high titers of viral stocks, for producing recombinant viral vectors, for testing samples, especially clinical samples for the presence of virus and for screening candidate compounds or drugs for anti-viral activity.

公开(公告)号：EP1855713A2

公开(公告)日：2007-11-21

申请号：EP05856779.3

申请日：2005-06-01

申请人： MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK ,  The University of Kentucky Research Foundation

发明人： PALESE, Peter ,  GARCIA-SASTRE, Adolfo ,  CHAMBERS, Thomas

IPC分类号： A61K39/00 ,  A61K39/295 ,  A61K39/12 ,  A61K39/145 ,  C12N15/64 ,  C12N5/00 ,  A61K39/116

CPC分类号： C12N7/00 ,  A61K39/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  C12N15/86 ,  C12N2760/16332 ,  C12N2760/16343 ,  C12N2760/16345 ,  C12N2760/16361 ,  C12N2810/6072

摘要： The present invention relates, in general, to attenuated equine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated equine influenza viruses having modifications to an equine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

公开(公告)号：EP1773384A2

公开(公告)日：2007-04-18

申请号：EP05856778.5

申请日：2005-06-01

申请人： THE MOUNT SINAI SCHOOL OF MEDICINE, OF THE CITY UNIVERSITY OF NEW YORK ,  ST. JUDE CHILDREN'S RESEARCH HOSPITAL ,  The United States of America as represented by the secretary of Agriculture

发明人： GARCIA-SASTRE, Adolfo ,  PALESE, Peter ,  LAGER, Kelly, M. ,  WEBSTER, Robert ,  RICHT, Juergen, A. ,  WEBBY, Richard, J.

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  C12N15/64 ,  C12N5/00 ,  A61K39/116

CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/544 ,  A61K2039/552 ,  A61K2039/58 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16061 ,  C12N2760/16121 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16171

摘要： The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

摘要翻译： 本发明一般涉及具有拮抗细胞干扰素（IFN）应答能力受损的减毒猪流感病毒，以及在疫苗和药物制剂中使用这种减毒病毒。 具体地，本发明涉及具有修饰的猪NS1基因的减毒猪流感病毒，其减少或消除NS1基因产物拮抗细胞IFN应答的能力。 这些病毒在体内复制，但表现出降低的复制，毒力和增加的衰减，因此非常适合用于活病毒疫苗和药物制剂。